and Forkhead/FOXO1. As with other molecularly targeted agents such as imatinib mesylate (Gleevec) and trastuzumab (Herceptin), the success of PI3K inhibitors will probably depend on the selection ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback